MDB Capital Upgrades Maxygen (MAXY) to Buy

January 7, 2008 8:17 AM EST Send to a Friend
Get Alerts MAXY Hot Sheet
Price: $2.53 --0%

Rating Summary:
    0 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 27 | Down: 26 | New: 17
Trade MAXY Now!
Join SI Premium – FREE
MDB Capital upgrades and reinstates its coverage on Maxygen (Nasdaq: MAXY) with a Buy rating and a $15 price target.

The firm said it is optimistic about the potential of MAXY-G34 and Maxygen's protein optimization pipeline and technology platform. Furthermore, MDB said that the Street is currently undervaluing Maxygen's stake in Codexis.

Maxygen, Inc., a biotechnology company, engages in the discovery, development, and commercialization of protein pharmaceuticals for treatment of disease and serious medical conditions.

You May Also Be Interested In





Related Categories

Upgrades

Add Your Comment